ROSA MARÍA
AYALA DÍAZ
Profesora titular de universidad
![Foto de ROSA MARÍA](/img/nophoto.png)
![Foto de Hospital de Gran Canaria Dr. Negrin](/img/noimage_org.png)
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Gran Canaria Dr. Negrin (15)
2024
-
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer
-
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
Haematologica
2023
-
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681
2022
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
2016
-
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Haematologica, Vol. 101, Núm. 8, pp. 926-931
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918
2011
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477